SCHEMBL13181749

SCHEMBL13181749

COC(=O)c1cccc2c1CN(Cl)CC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 3/20 0.45
WDR77 Q9BQA1 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TRPA1 O75762 4/20 0.43
DRD2 P14416 1/20 0.42
DRD1 P21728 1/20 0.42
DRD4 P21917 1/20 0.42
DRD5 P21918 1/20 0.42
C5AR1 P21730 1/20 0.41
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454882 0.84 PRMT5 (0.50) PRMT5WDR77MEN1KMT2ATRPA1
SCHEMBL14895892 0.80 KDM4E (0.48) PRMT5WDR77MEN1KMT2ATRPA1
SCHEMBL697731 0.78 SYK (0.45) PRMT5WDR77MEN1KMT2ATRPA1
SCHEMBL12583806 0.77 TNF (0.51) PRMT5WDR77MEN1KMT2ADRD2
SCHEMBL19739032 0.77 ESR2 (0.51) PRMT5WDR77C5AR1
SCHEMBL29663126 0.75 TRPA1 (0.44) PRMT5WDR77MEN1KMT2ATRPA1
SCHEMBL22859092 0.75 PRMT5 (0.47) PRMT5WDR77MEN1KMT2ATRPA1
SCHEMBL6232256 0.75 CXCR5 (0.50) MEN1KMT2ATRPA1LMNATSHR
SCHEMBL7408640 0.75 TRPA1 (0.49) MEN1KMT2ATRPA1LMNATSHR
SCHEMBL31305927 0.75 TRPA1 (0.49) MEN1KMT2ATRPA1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249102-A1 Heterotricyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) 2010-09-30 US disclosed
US-7749996-B2 Heterotricyclic metalloprotease inhibitors Alantos Pharmaceutical Holdings, Inc. (US) 2010-07-06 US disclosed
US-20100087420-A1 Heterotricyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) 2010-04-08 US disclosed
US-20080207607-A1 Heterotricyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087420-A1 Heterotricyclic Metalloprotease Inhibitors MMP13, MMP3, TIMP3 PRMT5 2533/4885WDR77 4217/4885MEN1 1345/4885
US-20100249102-A1 Heterotricyclic Metalloprotease Inhibitors MMP13, MMP3, TIMP3 PRMT5 2533/4885WDR77 4217/4885MEN1 1345/4885
US-20080207607-A1 Heterotricyclic metalloprotease inhibitors MMP13, MMP3, TIMP3 PRMT5 2533/4885WDR77 4217/4885MEN1 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.